MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2− metastatic breast cancer

PURPOSE: The phase 2 MONARCH 1 study was designed to evaluate the single-agent activity and adverse event (AE) profile of abemaciclib, a selective inhibitor of CDK4 and CDK6, in women with refractory hormone receptor positive (HR+), HER2− metastatic breast cancer (MBC). EXPERIMENTAL DESIGN: MONARCH...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Dickler, Maura N., Tolaney, Sara M., Rugo, Hope S., Cortés, Javier, Diéras, Véronique, Patt, Debra, Wildiers, Hans, Hudis, Clifford A., O’Shaughnessy, Joyce, Zamora, Esther, Yardley, Denise A., Frenzel, Martin, Koustenis, Andrew, Baselga, José
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5581697/
https://ncbi.nlm.nih.gov/pubmed/28533223
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-0754
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados